Skip to main content
OpenTrials

Clinical trial condition

Pseudomonas Aeruginosa in Cystic Fibrosis

Explore clinical trials studying Pseudomonas Aeruginosa in Cystic Fibrosis. Study availability and eligibility vary by location and protocol.

2 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Pseudomonas Aeruginosa in Cystic Fibrosis trial results

Completed

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

NCT02449031

Conditions
Pseudomonas Aeruginosa in Cystic Fibrosis
Locations
  • Novartis Investigative Site Anchorage, Alaska, United States
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Bellflower, California, United States
  • Novartis Investigative Site Fullerton, California, United States
View all 47 locations
View Trial Details
Completed

Long Term Safety of Tobramycin Inhalation Powder in Patients With Cystic Fibrosis

NCT01519661

Conditions
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis, Digestive System Diseases, +7 more
Locations
  • Novartis Investigative Site Little Rock, Arkansas, United States
  • Novartis Investigative Site Denver, Colorado, United States
  • Novartis Investigative Site Jacksonville, Florida, United States
  • Novartis Investigative Site Atlanta, Georgia, United States
View all 49 locations
View Trial Details

Related conditions